>Insulin-like Growth Factor（IGF）Family
Insulin-like growth factor (IGF) is a group of growth hormones that play a key role in regulating the signaling processes critical to cell proliferation, differentiation, and survival. These growth factors are expressed in various tissues and cell types, with autocrine, paracrine and endocrine functions. There are two types of IGFs, type I(IGF-I) and type II (IGF-II), act by binding to their specific membrane receptors: IGF-I R and IGF-II R.
As with IGF, IGF receptors are also potential targets for targeted therapies. IGF-I R is a heterotetrameric transmembrane protein with two disulfide-linked alpha subunits and two transmembrane beta subunits. Activation of this pathway has been linked to cancer initiation and growth, with many types of tumor cells overexpressing IGF-IR to promote resistance to radiotherapy, chemotherapy and targeted therapies. To overcome this resistance, IGF / IGF-IR targeted therapies have become a viable cancer treatment strategy. Teprotumumab, a representative drug targeting IGF-IR, was approved by the US Food and Drug Administration (FDA) in 2020 for the treatment of thyroid-associated ophthalmopathy (TAO). Initial studies suggest that combined targeting of IGF-IR and STAT3 may inhibit tumor metastasis and overcome resistance to STAT3-mediated anti-IGF-IR therapy, maximizing the efficacy of cancer treatment.
Schematic diagram of IGF-targeted drugs
Therapeutic strategies to inhibit IGF-IR signaling
ACROBiosystems has developed a series of HEK293-expressed IGF and IGF receptor family proteins, including IGF-IR tetrameric protein, IGF-I, IGF-II, IGFBP-3, IGFBP-4 and IGFBP-7. The IGF family proteins are available in various species and tags, with high purity and high structural homogeneity verified by SDS-PAGE/SEC-MALS. High bioactivity was also validated by ELISA/SPR. Our proteins also undergo a strict quality control system to ensure stable performance in immunization, antibody drug screening and characterization studies to help drug development targeting IGF.
|Molecule||Cat. No.||Species||Product Description||Preorder/Order|
|IGF-I R||IGR-H5229||Human||Human IGF-I R / CD221 Protein, His Tag (MALS verified)|
|IGR-H82E3||Biotinylated Human IGF-I R / CD221 Protein, His,Avitag™|
|IGR-M5223||Mouse||Mouse IGF-I R / CD221 Protein, His Tag|
|IGR-C5225||Cynomolgus||Cynomolgus IGF-I R / CD221 Protein, His Tag (MALS verified)|
|IGR-R5224||Rat||Rat IGF-I R / CD221 Protein, His Tag (MALS verified)|
|IGF-I||IG1-H5245||Human||Human IGF-I Protein, His Tag (SPR verified)|
|IG1-H4269||Human IGF-I Protein, Fc Tag|
|IG1-H82Q6||Biotinylated Human IGF-I Protein, His,Avitag™ (SPR verified)|
|IG1-H82F7||Biotinylated Human IGF-I Protein, Avitag™,Fc Tag (MALS verified)|
|IG1-M5253||Mouse||Mouse IGF-I Protein, Fc Tag (MALS verified)|
|IGF-II||IG2-H4260||Human||Human IGF-II Protein, Fc Tag|
|IG2-H82Q6||Biotinylated Human IGF-II Protein, His,Avitag™|
|IG2-H82F9||Biotinylated Human IGF-II Protein, Avitag™,Fc Tag|
|IGFBP-3||IG3-H52H9||Human||Human IGFBP-3 Protein, His Tag|
|IGFBP-4||IG4-H52E4||Human||Human IGFBP-4 Protein, His Tag|
|IGFBP-7||IG7-H5240||Human||Human IGFBP-7 Protein, His Tag|
|IG7-H5259||Human IGFBP-7 Protein, Fc Tag (MALS verified)|
|IG7-H82Q9||Biotinylated Human IGFBP-7 Protein, His,Avitag™ (MALS verified)|
|IG7-H82F9||Biotinylated Human IGFBP-7 Protein, Fc,Avitag™ (MALS verified)|
The purity of Human IGF-I R, His Tag (Cat. No. IGR-H5229) is more than 90% and the molecular weight of this protein is around 252-308 kDa verified by SEC-MALS.
Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 0.01-0.625 μg/mL (QC tested).
Human IGFBP-7, His Tag (Cat. No. IG7-H5240) immobilized on CM5 Chip can bind Human C1q R1, His Tag (Cat. No. C11-H5228) with an affinity constant of 16.7 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
 Wang P, Mak V C Y, Cheung L W T. Drugging IGF-1R in cancer: new insights and emerging opportunities[J]. Genes & Diseases, 2022.https://doi.org/10.1016/j.gendis.2022.03.002.
 Lin S L, Lin C Y, Lee W, et al. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine[J]. International Journal of Molecular Sciences, 2022, 23(19): 11781.https://doi.org/10.3390/ijms231911781.
 Morrione A, Belfiore A. Obesity, Diabetes, and Cancer: The Role of the Insulin/IGF Axis; Mechanisms and Clinical Implications[J]. Biomolecules, 2022, 12(5): 612.https://doi.org/10.3390/biom12050612.
This web search service is supported by Google Inc.